These observations, taken together, suggest that IL6 can promote a FAM phenotype, which is associated with ILD severity, and that a mechanism of clinical efficacy of IL6 inhibition in ILD may be by altering macrophage biology. This evidence concerns the gene IL6 and interstitial lung disease.